1. Clinical & Scientific Overview
Paclitaxel IP (TIP-MED-000475, Reference Code [S3-BKLG-15]) is classified under
Oncology & Immunomodulators) as a Stage 3 Specialist Hospital Oncology & Transplant Formulary Module.
Within the Indian regulatory and compendial framework, it is governed under Schedule H / Specialist Hospital Prescription Only (Drugs Rules, 1945).
Co-indexed with Deferred to Dedicated Stage 3 Specialist Module (Not in Ch 03–12). Generic reference only; verify institutional oncology/ICU label.
Refer to approved institutional protocol & product label
3. Mechanism of Action & Pharmacodynamics
Specialist pharmacological agent co-indexed with Deferred to Dedicated Stage 3 Specialist Module (Not in Ch 03–12) (Stage 3 Specialist Hospital Oncology & Transplant Formulary Module).
4. Therapeutic Indications & Evidence-Supported Uses
- Specialist hospital, oncology, critical-care, or immunisation indication (Stage 3 Specialist Hospital Oncology & Transplant Formulary Module).
🇮🇳 Jurisdiction & Indication Note: Indications and schedules reflect Indian compendial and regulatory records (CDSCO / Indian Pharmacopoeia & NFI / NLEM 2022). Where international reference labels (US FDA DailyMed / NCBI StatPearls) are cited for pharmacokinetic or mechanistic parameters, international approvals do not automatically imply CDSCO approval in India.
5. Educational Dosage Context, Formulations & Administration
Educational Dosing & Regimen Summary: Educational Summary: Dosing strictly governed by specialist protocol (BSA mg/m² or weight mg/kg where applicable). Requires specialist oncology/critical-care dosing verification, BSA/weight protocol validation, and CDSCO statutory review prior to Stage 3 publication.
Administration & Meal Timing: Administer strictly under specialist supervision following institutional reconstitution and dilution standards.
6. Pharmacokinetics, Metabolism & Renal/Hepatic Adjustment
Specialist pharmacokinetic and organ-clearance profile; verify renal and hepatic function prior to each cycle/dose.
Hepatic/cellular biotransformation per drug class.
Assess baseline CrCl/eGFR before administration.
Assess baseline hepatic panel before administration.
7. Contraindications, Precautions & High-Risk Warnings
- Severe hypersensitivity; specific organ failure or pregnancy/lactation contraindications per approved product label.
Key Clinical Precautions: Requires specialist oncology/critical-care dosing verification, BSA/weight protocol validation, and CDSCO statutory review prior to Stage 3 publication.
8. Adverse Effects Profile
- Class-specific haematological, gastrointestinal, or infusion-related reactions; monitor closely.
- Myelosuppression, organ toxicity, or severe hypersensitivity; requires specialist monitoring.
9. Major Drug–Drug, Drug–Food & Drug–Herb Interactions
- Verify narrow-therapeutic-index, CYP450, QT-prolonging, and immunosuppressive interactions.
10. Clinical Monitoring, Patient Counselling & Storage
Clinical & Laboratory Monitoring: Baseline and serial CBC, renal function (SCr/eGFR), liver function tests (AST/ALT/bilirubin), and clinical vitals.
Pharmacist Patient Counselling Points:
- Counsel patient on indication, schedule adherence, infection/bleeding precautions, and urgent warning signs.
Storage, Stability & Dispensing Safeguards: Verify cold-chain (2°C–8°C) or cytotoxic hazardous-drug handling requirements on official label.
11. Visual Pharmacology & Mechanism Diagram (svg-v339-01-adme-12-step-journey)
12. Authoritative References, Regulatory Sources & Editorial Disclaimer
Primary Compendial & Guideline Reference: Indian Pharmacopoeia (IP 2022) • NLEM 2022 • CDSCO • NCBI Bookshelf
Official Verification Portals: Indian Pharmacopoeia Commission (IPC) & National Formulary of India (NFI) • Central Drugs Standard Control Organization (CDSCO) • Ministry of Health & Family Welfare — NLEM 2022 • NCBI Bookshelf / StatPearls Pharmacology Reference • DailyMed (US FDA Official Prescribing Reference)
Last Medically & Pharmaceutically Reviewed: 2026-11-10 • Verification Status: VERIFIED_EDUCATIONAL_CONTENT
Educational & Clinical Disclaimer: This reference profile is published solely for pharmacy education, academic study, and professional clinical reference. It does not substitute for patient-specific clinical judgement, qualified specialist oncology/medical supervision, or official CDSCO/IP prescribing information. Never self-medicate with prescription, Schedule H/H1/X, NDPS, or oncology medicines.
13. Related Reference Monographs, Educational Guides & Visual Concept
💊 Related Pharmacological / Category Profiles
- [S3-BKLG-12] Cyclophosphamide IP — Stage 3 Specialist Hospital Oncology & Transplant Formulary Modul
- [S3-BKLG-13] 5-Fluorouracil (5-FU) IP — Stage 3 Specialist Hospital Oncology & Transplant Formulary Modul
- [S3-BKLG-14] Doxorubicin Hydrochloride IP — Stage 3 Specialist Hospital Oncology & Transplant Formulary Modul
- [S3-BKLG-16] Imatinib Mesylate IP — Stage 3 Specialist Hospital Oncology & Transplant Formulary Modul